Nutra Pharma Corp
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment fo… Read more
Nutra Pharma Corp (NPHC) - Net Assets
Latest net assets as of September 2024: $-14.82 Million USD
Based on the latest financial reports, Nutra Pharma Corp (NPHC) has net assets worth $-14.82 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($558.84K) and total liabilities ($15.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.82 Million |
| % of Total Assets | -2651.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 703.33 |
Nutra Pharma Corp - Net Assets Trend (2001–2025)
This chart illustrates how Nutra Pharma Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nutra Pharma Corp (2001–2025)
The table below shows the annual net assets of Nutra Pharma Corp from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-12.38 Million | +10.10% |
| 2023-12-31 | $-13.77 Million | -11.24% |
| 2022-12-31 | $-12.38 Million | +40.71% |
| 2021-12-31 | $-20.88 Million | -251.68% |
| 2020-12-31 | $-5.94 Million | +49.26% |
| 2019-12-31 | $-11.70 Million | -97.10% |
| 2018-12-31 | $-5.94 Million | -9.73% |
| 2017-12-31 | $-5.41 Million | -20.85% |
| 2016-12-31 | $-4.48 Million | -25.25% |
| 2015-12-31 | $-3.57 Million | +0.57% |
| 2014-12-31 | $-3.59 Million | +14.80% |
| 2013-12-31 | $-4.22 Million | -17.98% |
| 2012-12-31 | $-3.58 Million | +8.56% |
| 2011-12-31 | $-3.91 Million | -54.77% |
| 2010-12-31 | $-2.53 Million | -120.80% |
| 2009-12-31 | $-1.14 Million | +55.23% |
| 2008-12-31 | $-2.56 Million | -30.91% |
| 2007-12-31 | $-1.95 Million | -4.82% |
| 2006-12-31 | $-1.86 Million | -182.63% |
| 2005-12-31 | $-659.13K | -1505.31% |
| 2004-12-31 | $46.90K | -98.66% |
| 2003-12-31 | $3.49 Million | +7836.51% |
| 2002-12-31 | $-45.08K | +66.44% |
| 2001-12-31 | $-134.35K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nutra Pharma Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7336582300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.04 Million | % |
| Other Comprehensive Income | $469.68K | % |
| Other Components | $53.67 Million | % |
| Total Equity | $-12.38 Million | 100.00% |
Nutra Pharma Corp Competitors by Market Cap
The table below lists competitors of Nutra Pharma Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Compagnie Industrielle et Financière d'Entreprises SA
PA:INFE
|
$1.41 Million |
|
Haffner Energy SA
PA:ALHAF
|
$1.41 Million |
|
ASM Automation Group Berhad
KLSE:0362
|
$1.41 Million |
|
Gujarat Raffia Industries Limited
NSE:GUJRAFFIA
|
$1.41 Million |
|
CPL Group Public Company Limited
BK:CPL
|
$1.41 Million |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
$1.40 Million |
|
Johan Holdings Bhd
KLSE:3441
|
$1.40 Million |
|
NorthView Acquisition Corporation Warrant
PINK:NVACW
|
$1.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nutra Pharma Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2025, total equity changed from -13,768,308 to -12,377,452, a change of 1,390,856.
- Net income of 8,176,871 contributed positively to equity growth.
- Other comprehensive income increased equity by 469,678.
- Other factors decreased equity by 7,255,693.
Equity Change Factors (2023 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $8.18 Million | +66.06% |
| Other Comprehensive Income | $469.68K | +3.79% |
| Other Changes | $-7.26 Million | -58.62% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nutra Pharma Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $-0.12 | $0.00 | x |
| 2002-12-31 | $-0.05 | $0.00 | x |
| 2003-12-31 | $3.61 | $0.00 | x |
| 2004-12-31 | $0.04 | $0.00 | x |
| 2005-12-31 | $-0.41 | $0.00 | x |
| 2006-12-31 | $-1.04 | $0.00 | x |
| 2007-12-31 | $-1.01 | $0.00 | x |
| 2008-12-31 | $-0.62 | $0.00 | x |
| 2009-12-31 | $-0.20 | $0.00 | x |
| 2010-12-31 | $-0.37 | $0.00 | x |
| 2012-12-31 | $-0.35 | $0.00 | x |
| 2013-12-31 | $-0.23 | $0.00 | x |
| 2014-12-31 | $-0.12 | $0.00 | x |
| 2015-12-31 | $-0.06 | $0.00 | x |
| 2016-12-31 | $-0.03 | $0.00 | x |
| 2017-12-31 | $-0.01 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2025-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nutra Pharma Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1865.70%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-743.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-170.91K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $93.77K |
| 2003 | -78.51% | 0.00% | 0.00x | 1.27x | $-3.09 Million |
| 2004 | -17028.45% | 0.00% | 0.00x | 12.66x | $-7.99 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.09 Million |
| 2006 | 0.00% | -12035.53% | 0.19x | 0.00x | $-2.24 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $30.32K |
| 2008 | 0.00% | -102895.13% | 0.04x | 0.00x | $-3.91 Million |
| 2009 | 0.00% | -372.43% | 0.49x | 0.00x | $-2.19 Million |
| 2010 | 0.00% | -213.78% | 1.90x | 0.00x | $-2.81 Million |
| 2012 | 0.00% | -1776.94% | 0.67x | 0.00x | $-3.25 Million |
| 2013 | 0.00% | -3554.04% | 0.94x | 0.00x | $-3.92 Million |
| 2014 | 0.00% | -426.07% | 1.54x | 0.00x | $-2.17 Million |
| 2015 | 0.00% | -1850.99% | 0.75x | 0.00x | $-5.03 Million |
| 2016 | 0.00% | -2047.81% | 0.79x | 0.00x | $-3.00 Million |
| 2017 | 0.00% | -3330.12% | 0.31x | 0.00x | $-3.49 Million |
| 2018 | 0.00% | 0.00% | -13.26x | 0.00x | $-3.29 Million |
| 2019 | 0.00% | -6314.07% | 0.31x | 0.00x | $-5.42 Million |
| 2020 | 0.00% | -6314.07% | 0.74x | 0.00x | $-6.00 Million |
| 2021 | 0.00% | -13399.01% | 0.13x | 0.00x | $-11.01 Million |
| 2022 | 0.00% | 1865.70% | 0.58x | 0.00x | $9.41 Million |
| 2023 | 0.00% | -234.22% | 0.93x | 0.00x | $-16.53K |
| 2025 | 0.00% | 1865.70% | 0.58x | 0.00x | $9.41 Million |
Industry Comparison
This section compares Nutra Pharma Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nutra Pharma Corp (NPHC) | $-14.82 Million | 0.00% | N/A | $1.41 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |